跳至主要内容
临床试验/ITMCTR2100004848
ITMCTR2100004848招募中1 期

Clinical study on the therapeutic effect of Juanbi Qianggu Formula combined with DMARDs on Rheumatoid Arthritis with liver and kidney deficiency

Shanghai Guanghua Integrated traditional Chinese and Western Medicine Hospital0 个研究点开始时间: 待定最近更新:
适应症

试验速览

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

性别
All

入选标准

  • 1. Agree to participate in this study and sign an informed consent form;
  • 2. Comply with the diagnostic criteria for rheumatoid arthritis stipulated in the classification standards of the American College of Rheumatology (ACR) in 1987 and the Chinese Medicine Industry Standards of the Peoples Republic of China Diagnosis and Efficacy Standards for Diseases and Symptoms of Traditional Chinese Medicine (ZY/T001.1-94) and Practical TCM Rheumatology (edited by Wang Chengde, Shen Pi'an, Hu Mengqi, People's Medical Publishing House, 2009) TCM Liver and Kidney Deficiency Type Kaibi Syndrome Differentiation Standard;
  • 3. DAS28 score <=5.1;
  • 4. TCM syndrome score >= 6 points.

排除标准

  • 1. Abnormal liver and kidney function;
  • 2. Pregnant women or breastfeeding women, mental patients;
  • 3. Patients with serious diseases such as heart, liver, brain, kidney and hematopoietic system;
  • 4. Overlap other rheumatic diseases such as systemic lupus erythematosus, Sjogrens syndrome, severe knee osteoarthritis ;
  • 5. Patients with advanced stage, severe joint deformity, and grade IV joint function;
  • 6. Those who have received other study drugs 3 months before screening;
  • 7. Those who are unable or unwilling to provide informed consent or unable to comply with the test requirements;
  • 8. Researchers believe that it is not suitable for all subjects participating in this study.

研究者

相似试验